Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

FF-10502

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Fujifilm Holdings

Drug class:

DNA synthesis inhibitor

Related drugs:

‹

captisol-enabled melphalan (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

cytarabine/daunorubicin liposomal formulation (19)

clofarabine (16)

carmustine (14)

temozolomide gel (7)

fludarabine IV (6)

hydroxyurea (3)

mercaptopurine (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine-releasing intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

›

BAP1 mutation	Cholangiocarcinoma	BAP1 mutation	Cholangiocarcinoma	FF-10502 Sensitive: C3 – Early Trials FF-10502 Sensitive : C3	FF-10502 Sensitive: C3 – Early Trials FF-10502 Sensitive : C3
PBRM1 mutation	Cholangiocarcinoma	PBRM1 mutation	Cholangiocarcinoma	FF-10502 Sensitive: C3 – Early Trials FF-10502 Sensitive : C3	FF-10502 Sensitive: C3 – Early Trials FF-10502 Sensitive : C3